Please assess the completion status of the following clinical trial:

Trial Title: Development of an Intranasal Proteosome Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Young healthy adults as determined by medical history, physical examination, serology (HIV and Hepatitis B and C) and clinical laboratory tests.~* Female subjects were required to provide of a history of reliable contraceptive practice.~* Susceptibility to A/Panama/2007/1999 (H3N2) (a serum reciprocal HAI titre ≤10) was confirmed at screening. -~Exclusion Criteria:included;~* asthma,~* hypersensitivity to mercurials or chicken eggs,~* anatomic or neurologic abnormality impairing the gag reflex or contributing to aspiration, \* chronic nasopharyngeal complaints,~* abnormal electrocardiogram (ECG),~* febrile illness or significant symptoms of upper respiratory infection on the day of vaccination or between admission to quarantine and administration of the challenge inoculum.~* Subjects using medication or other products for rhinitis or nasal congestion,~* Subject who had received systemic glucocorticoids within 1 month, or cytotoxic or immunosuppressive drugs within 6 months of the study start.~* Subjects agreed not to smoke during the quarantine phase.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Protesomal Vaccine 1 x 30 µg (Type: EXPERIMENTAL): Protesomal Vaccine 1 x 30 µg
- Protesomal Vaccine 2 x 30 µg (Type: EXPERIMENTAL): Protesomal Vaccine 2 x 30 µg
- Protesomal Vaccine 2 x 15 µg (Type: EXPERIMENTAL): Protesomal Vaccine 2 x 15 µg

Based on this trial design, predict the completion outcome and termination type (if applicable).